Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease

Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease

The purpose of the study is to evaluate whether Oncoxin, a nutritional supplement, improves the clinical and ultrasonographic results in comparison with placebo during 24 weeks of treatment.

Inclusion Criteria:

• Patients with clinical and ultrasonographic confirmation of breast fibrocystic disease.
• Patients older than 20 years.
• Female patients.
• Informed consent.

Exclusion Criteria:

• Presents of another disease not well controlled.
• Pregnant women or lactating.
• Patient which are receiving another products from other investigations trials.